CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 11 enrolled
Drug / intervention
1072nm infrared Photobiomodulation +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01059877
NCT01059877N/ACompleted
CompareCT.gov

Assessing the Effect of 1072nm Infrared (IR) Phototherapy on the Behavioral and Cognitive Symptoms Associated With Early and Mid-stage Dementia: a Randomized Placebo-controlled Clinical Trial.

Quietmind Foundation·interventional·Posted Feb 1, 2010·Updated Sep 27, 2018

In Brief

A clinical study evaluating 1072nm infrared Photobiomodulation and Photobiomodulation SIMULATED for Dementia. Completed, enrolled 11 participants across 1 site.

Detailed Summary

This study will employ a double-blind, placebo-controlled approach to assess the effect of 1072nm infrared (IR) phototherapy on the behavioral and cognitive symptoms associated with early and mid-stage dementia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDementia
CountriesUnited States
CollaboratorsMaculume Ltd.

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 1, 2010
Enrollment StartJan 1, 2010
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 16.4 years ago

Interventions

1072nm infrared Photobiomodulationdevice

1072nm infrared light delivering 2.6 Joules (2.6J)/sq cm over a 6 minute treatment period.

Photobiomodulation SIMULATEDdevice

Device mounted and procedure followed but with no stimulation.